Type 1 diabetes is a chronic disease caused by autoimmune destruction of pancreatic
β cells. Individuals with type 1 diabetes are reliant on insulin for survival. Despite
enhanced knowledge related to the pathophysiology of the disease, including interactions
between genetic, immune, and environmental contributions, and major strides in treatment
and management, disease burden remains high. Studies aimed at blocking the immune
attack on β cells in people at risk or individuals with very early onset type 1 diabetes
show promise in preserving endogenous insulin production.
Combined advances in haematopoietic cell transplantation (HCT) and intensive care
management have improved the survival of patients with haematological malignancies
admitted to the intensive care unit. In cases of refractory respiratory failure or
refractory cardiac failure, these advances have led to a renewed interest in advanced
life support therapies, such as extracorporeal membrane oxygenation (ECMO), previously
considered inappropriate for these patients due to their poor prognosis. Given the
scarcity of evidence-based guidelines on the use of ECMO in patients receiving HCT
and the need to provide equitable and sustainable access to ECMO, the European Society
of Intensive Care Medicine, the Extracorporeal Life Support Organization, and the
International ECMO Network aimed to develop an expert consensus statement on the use
of ECMO in adult patients receiving HCT.
Respiratory syncytial virus (RSV) is a major cause of hospital admissions in young
children, with the highest burden in infants younger than 3 months. A birth cohort
study done in five European countries between 2017 and 2021 found that 1·8% of term-born
children are admitted to hospital due to RSV infection in the first year of life.1
More than half of children who required hospital admission were younger than 3 months.
Until November, 2022, immunisation strategies against RSV were restricted to groups
at high risk of severe outcomes; however, on Oct 31, 2022, the human monoclonal antibody
nirsevimab was approved by the European Medicines Agency to protect all infants during
their first RSV season.
/PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec) was granted authorization by the Medicines and.
PTC Therapeutics (PTCT) Announces Upstaza Granted Marketing Authorization for AADC deficiency in UK streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.